Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study

The data of sequential therapy of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in clinical practice have been limited. We reviewed the clinical data of patients with ALK-rearranged non-small cell lung cancer who received crizotinib (CRZ) or alectinib (ALEC) between May 2012 and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2021-03, Vol.145, p.183-193
Hauptverfasser:	Ito, Kentaro, Yamanaka, Takeharu, Hayashi, Hidetoshi, Hattori, Yoshihiro, Nishino, Kazumi, Kobayashi, Haruki, Oya, Yuko, Yokoyama, Toshihide, Seto, Takashi, Azuma, Koichi, Fukui, Tomoya, Kozuki, Toshiyuki, Nakamura, Atsushi, Tanaka, Kentaro, Hirano, Katsuya, Yokoi, Takashi, Daga, Haruko, Sakata, Shinya, Fujimoto, Daichi, Mori, Masahide, Maeno, Ken, Aoki, Takuya, Tamura, Atsuhisa, Miura, Satoru, Watanabe, Satoshi, Akamatsu, Hiroaki, Hataji, Osamu, Suzuki, Kensuke, Hontsu, Shigeto, Azuma, Koji, Bessho, Akihiro, Kubo, Akihito, Okuno, Motoyasu, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Alectinib Anaplastic lymphoma kinase Cohort analysis Crizotinib Inhibitor drugs Kinases Lung cancer Lymphoma Non-small cell lung cancer Non-small cell lung carcinoma Patients Protein-tyrosine kinase Real-world data Sequential therapy Small cell lung carcinoma Targeted cancer therapy Therapy Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!